Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Cantor Fitzgerald analyst Carter Gould has maintained an Overweight rating on AbbVie (NYSE: ABBV) and raised the price target from $285 to $290. This adjustment reflects a positive outlook on the company's performance.